Market Place
Sourcing Support
Baudax Bio Announces Corporate Update
18 Oct 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168
28 Sep 2023 //
GLOBENEWSWIRE
Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Baudax Announces Distribution of Series C Preferred Stock to Holders of Stock
23 Aug 2023 //
GLOBENEWSWIRE
Baudax Bio Announces $1.9M Registered Direct Offering Priced under Nasdaq Rules
17 Aug 2023 //
GLOBENEWSWIRE
Baudax Bio Reports Second Quarter 2023 Financial Results
16 Aug 2023 //
GLOBENEWSWIRE
Baudax Bio Acquires TeraImmune, Inc.
30 Jun 2023 //
GLOBENEWSWIRE
Baudax Bio reports promising additional data for neuromuscular blockade agent
07 Jun 2023 //
CLINICAL TRIALS ARENA
Baudax Bio Announces Results From Phase 2 Randomized Clinical Trial of BX1000
07 Jun 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Date of Reconvened Annual Meeting
06 Jun 2023 //
GLOBENEWSWIRE
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
12 May 2023 //
GLOBENEWSWIRE
Baudax Bio to Present at the Sidoti Virtual Investor Conference
03 May 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Closing of $4 Million Public Offering
01 May 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Pricing of $4 Million Public Offering
26 Apr 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Positive Top-Line Final Results From Ph2 Trial of BX1000
25 Apr 2023 //
GLOBENEWSWIRE
Baudax to Host Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
24 Apr 2023 //
GLOBENEWSWIRE
Baudax Announces Positive Results from Phase 2 Randomized Trial for BX1000
27 Mar 2023 //
GLOBENEWSWIRE
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
Baudax Bio Announces Positive Outcome of PII Randomized Trial for BX1000
24 Jan 2023 //
GLOBENEWSWIRE
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients
08 Dec 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Closing of $5 Million Public Offering
06 Dec 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Pricing of $5 Million Public Offering
02 Dec 2022 //
GLOBENEWSWIRE
Baudax Bio Announces 1-for-40 Reverse Stock Split
30 Nov 2022 //
GLOBENEWSWIRE
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights
08 Nov 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Distribution of Series B Preferred Stock
19 Sep 2022 //
GLOBENEWSWIRE
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference
08 Sep 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Closing of $6.2 Million Public Offering
01 Sep 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Pricing of $6.2 Million Public Offering
29 Aug 2022 //
GLOBENEWSWIRE
Baudax receives notice of allowance for U.S. Patent Application covering ANJESO
22 Aug 2022 //
GLOBENEWSWIRE
Baudax Bio Reports Second Quarter 2022 Financial Results and Business Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Dosing of First Cohort in PI Study of BX2000
01 Jun 2022 //
GLOBENEWSWIRE
Baudax Bio Announces $2.0M Registered Direct Offering
17 May 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
05 May 2022 //
GLOBENEWSWIRE
Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights
04 May 2022 //
GLOBENEWSWIRE
Baudax Bio to Report First Quarter 2022 Financial Results
02 May 2022 //
GLOBENEWSWIRE
Baudax Bio to Present at NobleCon18 Investor Conference
13 Apr 2022 //
GLOBENEWSWIRE
Baudax Bio Reports 2021 Q4 and Annual Financial Results
16 Mar 2022 //
GLOBENEWSWIRE
Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
10 Mar 2022 //
GLOBENEWSWIRE
Baudax Bio Initiates Phase IV Trial Evaluating ANJESO
08 Mar 2022 //
GLOBENEWSWIRE
Baudax Bio Regains Compliance with NASDAQ Listing Requirements
07 Mar 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Seventh Orange Book Listable Patent for ANJESO®
02 Mar 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Proposed Public Offering of Securities
24 Feb 2022 //
GLOBENEWSWIRE
Baudax Bio Announces Pricing of $10.0 Million Public Offering
24 Feb 2022 //
GLOBENEWSWIRE
Baudax Bio Announces 1-for-35 Reverse Stock Split
15 Feb 2022 //
GLOBENEWSWIRE
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31 Dec 2021 //
GLOBENEWSWIRE
Baudax Bio Announces $4.2 Million Registered Direct Offering
28 Dec 2021 //
GLOBENEWSWIRE
Baudax Bio to Participate in the Piper Sandler 33rd Annual VHC
15 Nov 2021 //
GLOBENEWSWIRE
Baudax Bio Announces Clinical Program Update for Neuromuscular Blocking Agents
11 Nov 2021 //
GLOBENEWSWIRE
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Oct 2021 //
GLOBENEWSWIRE
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Oct 2021 //
GLOBENEWSWIRE
Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences
16 Sep 2021 //
GLOBENEWSWIRE
Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares
30 Jun 2021 //
GLOBENEWSWIRE
Baudax Bio’s ANJESO Achieves Formulary Listing at Over 100 Institutions
08 Jun 2021 //
GLOBENEWSWIRE
Baudax Bio Announces Publication of Phase IIIb ANJESO® Data
17 May 2021 //
GLOBENEWSWIRE
Baudax Bio Announces Publication of Pha IIIb Data on Preoperative of ANJESO®
26 Apr 2021 //
GLOBENEWSWIRE
Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million
21 Jan 2021 //
GLOBENEWSWIRE
Baudax Bio Announces $12 Million Offering Priced at a Premium to Market
17 Dec 2020 //
GLOBENEWSWIRE
Baudax Bio Announces $12 Million Offering Priced at a Premium to Market
17 Dec 2020 //
GLOBENEWSWIRE
Baudax Bio Provides Commercial and Corporate Update
20 Oct 2020 //
GLOBENEWSWIRE
Baudax Bio to Present at Oppenheimer Fall Healthcare LS & Medtech Summit
18 Sep 2020 //
BIOSPACE
